Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SB WILL BE ONE OF A HANDFUL OF "GLOBAL MEGAPLAYERS" BY THE YEAR 2000, CEO LESCHLY PREDICTS; $2.6 BIL. POST-TRANSITION DEBT PAYOFF SEEN BY END OF 1997

Executive Summary

SmithKline Beecham will be one of only five to 10 or a "handful or two" of global pharmaceutical and healthcare management companies in existence by the year 2000, SB CEO Jan Leschly predicted at a Dec. 12 meeting with securities analysts in New York City.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel